Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with fluorouracil-based chemotherapy: A study to determine recommendable therapeutic dosage

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 2, 2003, Pages 107-111

  Viéitez, Jose M ^a   Carrasco, Juan ^b   Esteban, Emilio ^b   Fra, Joaquín ^b   Alvarez, Elena ^b   Muñiz, Isabel ^b   Sala, Marian ^b   Buesa, Jose M ^b   Jiménez Lacave, Angel ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b NONE

Author keywords

Colon cancer; Irinotecan; Phase I trial; Recommended dose

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED; TEGAFUR; URACIL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PALLIATIVE CARE; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 0344519764     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200304000-00001     Document Type: Article

References (31)

1. Cohen AM, Minsky BD, Schilky RL. Cancer of the colon. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997:1145-1197.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
3. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
4. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1009;352:1413-1418.
5. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071.
6. Punt CJA. "Hold the Mayo": solid factors or pulp fiction? [Editorial]. Ann Oncol 2000;11:919-920.
7. Saltz LB, Cox JV, Blanke CH, et al. Irinotecan, plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 2000;355:1041-1047.
9. Mayer RJ. Newer cytotoxic agents for advanced colon cancer. Am Soc Clin Oncol Educational Books; 2000:625-630.
10. Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-221.
11. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every three weeks. Cancer Res 1994;54:427-436.
12. Taguchi T, Wakui A, Hasegawa K, et al. Phase I clinical study of CPT-11. Research group of CPT-11. Jpn J Cancer Chemother 1990;7:115-120.
13. Carter SK. Clinical trials in cancer chemotherapy. Cancer 1977;40:544-557.
14. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-1147.
15. Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther 1989;46:63-77.
16. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
17. Von Hoff DD, Kuhn J, Clark GM. Design and conduct of phase I trials. In: Buyse ME, Staguet MJ, Sylvester RJ, eds. Cancer clinical trials (methods and practice). New York: Oxford University Press, 1984:210-219.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
19. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997;15:2910-2919.
20. Von Hoff DD, Rothenberg ML, Pitot HC, et al. Irinotecan therapy for patients with previously treated metastatic colorectal cancer: FDA results of FDA-reviewed pivotal US clinical trials [Abstract]. Proc Am Soc Clin Oncol 1997;16:228.
21. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-715.
22. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-260.
23. Kohne CH, Thuss-Patience P, Catane R, et al. Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer [Abstract 993]. Proc ASCO 1999;18:258.
24. Pitot HC. US pivotal studies of irinotecan in colorectal carcinoma. Oncology 1998;12:48-53.
25. Egner JR, Goldberg RM, Sargent DJ, et al. CPT-11 at 320 mg/m2 caused excessive toxicity in patients with advanced adenocarcinoma of the stomach of gastroesophageal junction: a North Central Cancer treatment Group Trial [Abstract 1084]. Proc ASCO 1999;18:282.
26. Van Cutsem E, Dirix L, Van Laethem J, et al. A randomized phase II trial of three different regimens of irinotecan: a fixed dose of 350 mg/m2, or an individual dose optimisation or a risk factor optimisation in patients with metastatic colorectal cancer [Abstract 946]. Proc ASCO 2000;19:244.
27. Shimada Y, Yoshino M, Wakui A, et al. and the CPT-11 Gastrointestinal Cancer Study Group. Phase II Study of CPT-11, a new camptothecin derivate, in metastatic colorectal cancer. J Clin Oncol 1993;11:909-913.
28. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-1135.
29. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil. Eur J Cancer 1999;35:54-59.
30. Saltz LB, Cox JV, Blanke CH, et al. Irinotecan, plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
31. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 2000;355:1041-1047.